Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma | Haematologica
![Proposed algorithm for the treatment of 'initial' , 'intermediate' or... | Download Scientific Diagram Proposed algorithm for the treatment of 'initial' , 'intermediate' or... | Download Scientific Diagram](https://www.researchgate.net/publication/321928456/figure/fig1/AS:573457671704576@1513734371915/Proposed-algorithm-for-the-treatment-of-initial-intermediate-or-advanced-myeloma.png)
Proposed algorithm for the treatment of 'initial' , 'intermediate' or... | Download Scientific Diagram
![Cancers | Free Full-Text | Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors Cancers | Free Full-Text | Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors](https://www.mdpi.com/cancers/cancers-13-04320/article_deploy/html/images/cancers-13-04320-g003.png)
Cancers | Free Full-Text | Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
![Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology](https://media.springernature.com/lw812/springer-static/esm/art%3A10.1007%2Fs00277-023-05188-4/MediaObjects/277_2023_5188_Fig4_ESM.png)
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology
![First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios ... First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios ...](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121021157-gr1.jpg)
First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios ...
![Cancers | Free Full-Text | Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice Cancers | Free Full-Text | Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice](https://pub.mdpi-res.com/cancers/cancers-15-02160/article_deploy/html/images/cancers-15-02160-g002.png?1681114532)
Cancers | Free Full-Text | Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
![Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments](https://www.frontiersin.org/files/Articles/624661/fonc-10-624661-HTML/image_m/fonc-10-624661-g001.jpg)
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
![PDF] Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Semantic Scholar PDF] Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/56aa3d90b9a446bab47d202f57de1e938c136ca3/6-Figure2-1.png)
PDF] Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Semantic Scholar
![Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Leukemia Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fleu.2017.329/MediaObjects/41375_2018_Article_BFleu2017329_Fig3_HTML.jpg)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Leukemia
![Decisional tree in the management of relapsed MM. IMWG International... | Download Scientific Diagram Decisional tree in the management of relapsed MM. IMWG International... | Download Scientific Diagram](https://www.researchgate.net/publication/333007606/figure/fig2/AS:962678826733568@1606531926285/Decisional-tree-in-the-management-of-relapsed-MM-IMWG-International-Myeloma-Working.png)
Decisional tree in the management of relapsed MM. IMWG International... | Download Scientific Diagram
![Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-022-00757-8/MediaObjects/41408_2022_757_Fig5_HTML.png)
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal
![Suggested treatment options for newly diagnosed multiple myeloma (MM)... | Download Scientific Diagram Suggested treatment options for newly diagnosed multiple myeloma (MM)... | Download Scientific Diagram](https://www.researchgate.net/publication/347277088/figure/fig1/AS:11431281210530803@1702051129341/Suggested-treatment-options-for-newly-diagnosed-multiple-myeloma-MM-patients_Q320.jpg)
Suggested treatment options for newly diagnosed multiple myeloma (MM)... | Download Scientific Diagram
![Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology](https://media.springernature.com/lw812/springer-static/esm/art%3A10.1007%2Fs00277-023-05188-4/MediaObjects/277_2023_5188_Fig6_ESM.png)
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis | Annals of Hematology
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
![Multiple Myeloma Hub on X: "CONGRESS| #EMN2021|Sonja Zweegman discussed frailty subgroup analysis of the MAIA trial-dara-Rd vs Rd in transplant-ineligible patients with newly diagnosed MM. Dara-Rd reduced risk of PD or death Multiple Myeloma Hub on X: "CONGRESS| #EMN2021|Sonja Zweegman discussed frailty subgroup analysis of the MAIA trial-dara-Rd vs Rd in transplant-ineligible patients with newly diagnosed MM. Dara-Rd reduced risk of PD or death](https://pbs.twimg.com/media/Evzl92gXAAEQuQ2.jpg:large)
Multiple Myeloma Hub on X: "CONGRESS| #EMN2021|Sonja Zweegman discussed frailty subgroup analysis of the MAIA trial-dara-Rd vs Rd in transplant-ineligible patients with newly diagnosed MM. Dara-Rd reduced risk of PD or death
![Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020 Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020](https://www.mdpi.com/cancers/cancers-12-02885/article_deploy/html/images/cancers-12-02885-g001-550.jpg)
Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
HealthTree for Multiple Myeloma - NEXT WEDNESDAY🗓 Learn about the nationwide ECOG/SWOG clinical trial, ECOG DETER SMM in which a Dara Rd regimen is being compared to Rd treatment for smoldering myeloma
![Progression-free survival of Dara Rd vs Rd patients with 1–3 previous... | Download Scientific Diagram Progression-free survival of Dara Rd vs Rd patients with 1–3 previous... | Download Scientific Diagram](https://www.researchgate.net/publication/370223051/figure/fig2/AS:11431281157883497@1683942855783/Progression-free-survival-of-Dara-Rd-vs-Rd-patients-with-1-3-previous-treatment-lines.png)